Cochlear saw the highest growth of 1.05% in patent filings in June and 1.09% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.85% and grants by 0.9%. GlobalData’s DataBook provides a comprehensive analysis of Cochlear‘s patent filings and grants. Buy the databook here.
Cochlear has been focused on protecting inventions in United States(US) with 60 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 75% filings and 63% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Cochlear is filings its patents. Among the top granted patent authorities, Cochlear has 63% of its grants in United States(US), 30% in European Patent Office(EPO) and 7% in Australia(AU).
Demant could be the strongest competitor for Cochlear
Patents related to healthtech and smart hospitals lead Cochlear's portfolio
Cochlear has the highest number of patents in healthtech followed by, smart hospitals and smart materials. For healthtech, nearly 25% of patents were filed and 16% of patents were granted in Q2 2024.
Ent devices related patents lead Cochlear portfolio followed by other communications equipment, and neurology devices
Cochlear has highest number of patents in ent devices followed by other communications equipment, neurology devices, other remote patient monitoring, and healthcare it. For ent devices, nearly 36% of patents were filed and 36% of patents were granted in Q2 2024.
For comprehensive analysis of Cochlear's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.